Future Science Group launches new journal Future Drug Discovery

Led by an expert international Editorial Advisory Board, Future Drug Discovery is a peer-reviewed, open access journal covering the latest breakthrough science in drug discovery, research & development.

“The field of drug discovery has historically been troubled by high failure rates, and multidisciplinary research and access to data are being increasingly embraced in order to improve success,” commented Francesca Lake, Head of Open Access Publishing at Future Science Group. “Our intention is that Future Drug Discovery will harness these concepts, presenting new advances and discussing their applications and translation in an openly accessible format, and providing a forum for discussing the field at large.”

The journal’s Editorial Advisory Board includes David Clark (Charles River Laboratories), Steve Rees (Astrazeneca), Johannes Reynisson (University of Auckland), Rob Williams and Neil Jones (Cancer Research UK), Edgar Jacoby (Janssen), Giulia Caron (University of Torino), Dave C Morris (University of North Carolina at Chapel Hill), Francis Wilson (Summit Therapeutics), Xingcai Zhang (Harvard University) and Jayanth Panyam (University of Minnesota).

“In early drug discovery, time is extremely valuable,” said David Clark, PhD, Research Leader, CADD. “Open access to research, which Future Drug Discovery will provide, empowers researchers with information they need to make critical decisions earlier in the process.”

Future Drug Discovery will be a quarterly publication publishing case histories, methodologies, original research, reviews and opinion articles covering the entire drug discovery pipeline, plus topics of interest of interest to the drug discovery community. A comprehensive list of topics can be found at the journal webpage.

The journal’s latest content, which includes a forward-looking perspective on publishing in drug discovery, an editorial on open science in rare diseases research, and a research article examining experimental lipophilicity for beyond Rule of 5 compounds, is available ahead of print here: https://www.future-science.com/journal/fdd

###

The editorial office is now actively soliciting contributions of original research, reviews and opinion pieces for Future Drug Discovery. Unsolicited article proposals are also welcome, so if you are interested in contributing to the journal, please contact the Managing Editor, Francesca Lake at [email protected].

Founded in 2001, Future Science Group (FSG) is a progressive publisher focused on breakthrough medical, biotechnological, and scientific research. FSG’s portfolio includes two imprints, Future Science and Future Medicine. In addition to this core publishing business, FSG develops specialist eCommunities. Key titles and sites include Bioanalysis Zone, Epigenomics, Nanomedicine and the award-winning Regenerative Medicine.

The aim of FSG is to service the advancement of clinical practice and drug research by enhancing the efficiency of communications among clinicians, researchers and decision-makers, and by providing innovative solutions to their information needs. This is achieved through a customer-centric approach, use of new technologies, products that deliver value-for-money and uncompromisingly high standards.